Eva C. Kaltenthaler

30 Regent Street
Sheffield, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.

Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.

Journal: Health technology assessment (Winchester, England)

Published: March 02, 2019

Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Journal: PharmacoEconomics

Published: December 14, 2018

Delphi consensus reached to produce a decision tool for SelecTing Approaches for Rapid Reviews (STARR).

Delphi consensus reached to produce a decision tool for SelecTing Approaches for Rapid Reviews (STARR).

Journal: Journal of clinical epidemiology

Published: December 14, 2018

Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Journal: PharmacoEconomics

Published: September 25, 2018

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.

Journal: Applied health economics and health policy

Published: May 29, 2018

Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process.

Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process.

Journal: PharmacoEconomics - open

Published: February 15, 2018

Patient-Reported Outcome Measures in Carotid Artery Revascularization: Systematic Review and Psychometric Analysis.

Patient-Reported Outcome Measures in Carotid Artery Revascularization: Systematic Review and Psychometric Analysis.

Journal: Annals of vascular surgery

Published: October 16, 2017

Nature and reporting characteristics of UK health technology assessment systematic reviews.

Nature and reporting characteristics of UK health technology assessment systematic reviews.

Journal: BMC medical research methodology

Published: September 15, 2017

Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Journal: PharmacoEconomics

Published: August 04, 2017

Systematic review assessing the measurement properties of patient-reported outcomes for venous leg ulcers.

Systematic review assessing the measurement properties of patient-reported outcomes for venous leg ulcers.

Journal: BJS open

Published: June 19, 2017

What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?

What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: March 31, 2017

Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Journal: PharmacoEconomics

Published: February 09, 2017

Showing 1-12 of 49

Last Updated: 09/26/2026